NASDAQ:ZNTL Zentalis Pharmaceuticals (ZNTL) Stock Price, News & Analysis $1.36 -0.13 (-8.72%) Closing price 04:00 PM EasternExtended Trading$1.37 +0.01 (+0.74%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Zentalis Pharmaceuticals Stock (NASDAQ:ZNTL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ZNTL alerts:Sign Up Key Stats Today's Range$1.36▼$1.5250-Day Range$1.49▼$3.8052-Week Range$1.28▼$6.95Volume1.21 million shsAverage Volume1.53 million shsMarket Capitalization$97.47 millionP/E RatioN/ADividend YieldN/APrice Target$8.29Consensus RatingModerate Buy Company Overview Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for cancer. Its research centers on therapies that target biological processes involved in tumor growth. The company’s lead drug candidate, azenosertib (formerly known as ZN-c3), is an investigational inhibitor of WEE1, a protein involved in cell-cycle regulation. It has been studied in clinical trials for ovarian cancer and other solid tumors. Zentalis has also advanced other oncology drug candidates, including compounds targeting cancer-related proteins. Founded in 2014, Zentalis is based in the United States and conducts clinical development for potential cancer treatments. Its drug candidates remain investigational; the company’s focus is on research and development rather than marketing approved medicines.AI Generated. May Contain Errors. Read More Zentalis Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreZNTL MarketRank™: 4.16733173716 of 5 starsZentalis Pharmaceuticals scored higher than 83% of companies evaluated by MarketBeat, and ranked 58th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingZentalis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialZentalis Pharmaceuticals has a consensus price target of $8.29, representing about 481.5% upside from its current price of $1.43.Amount of Analyst CoverageZentalis Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Zentalis Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Zentalis Pharmaceuticals are expected to grow in the coming year, from ($1.80) to ($1.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zentalis Pharmaceuticals is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zentalis Pharmaceuticals is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZentalis Pharmaceuticals has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.30% of the float of Zentalis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverZentalis Pharmaceuticals has a short interest ratio ("days to cover") of 3.49, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zentalis Pharmaceuticals has recently decreased by 15.87%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZentalis Pharmaceuticals does not currently pay a dividend.Dividend GrowthZentalis Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.73 News SentimentZentalis Pharmaceuticals has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Zentalis Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest5 people have searched for ZNTL on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows5 people have added Zentalis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zentalis Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders3.80% of the stock of Zentalis Pharmaceuticals is held by insiders.Percentage Held by InstitutionsZentalis Pharmaceuticals has minimal institutional ownership at this time.Read more about Zentalis Pharmaceuticals' insider trading history. Receive ZNTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZNTL Stock News HeadlinesHC Wainwright Has Positive Outlook for ZNTL FY2026 EarningsNovember 14, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Olema Pharmaceuticals (OLMA) and Zentalis Pharmaceuticals (ZNTL)November 12, 2026 | theglobeandmail.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 18 at 1:00 AM | Weiss Ratings (Ad)Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Rating Upgraded by WedbushNovember 12, 2026 | americanbankingnews.comMorgan Stanley Remains a Hold on Zentalis Pharmaceuticals (ZNTL)November 11, 2026 | theglobeandmail.comZentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business UpdatesNovember 9, 2026 | globenewswire.comZentalis Pharmaceuticals (ZNTL) Expected to Post Quarterly Earnings on TuesdayNovember 9, 2026 | americanbankingnews.comZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 3, 2026 | globenewswire.comSee More Headlines ZNTL Stock Analysis - Frequently Asked Questions How have ZNTL shares performed this year? Zentalis Pharmaceuticals' stock was trading at $1.35 at the beginning of 2026. Since then, ZNTL stock has increased by 5.6% and is now trading at $1.4250. How were Zentalis Pharmaceuticals' earnings last quarter? Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) posted its earnings results on Monday, November, 9th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.20. When did Zentalis Pharmaceuticals IPO? Zentalis Pharmaceuticals (ZNTL) raised $156 million in an initial public offering on Friday, April 3rd 2020. The company issued 9,180,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO. Who are Zentalis Pharmaceuticals' major shareholders? Top institutional investors of Zentalis Pharmaceuticals include State Street Corp (1.55%), Soleus Capital Management L.P. (0.99%), Marshall Wace LLP (0.60%) and Goldman Sachs Group Inc. (0.26%). Insiders that own company stock include Group Walters, Matrix Capital Management Comp, Cam Gallagher, Melissa B Epperly, Scott Dunseth Myers, Mark Lackner, Jan Skvarka, Vincent Vultaggio and Ingmar Bruns. View institutional ownership trends. How do I buy shares of Zentalis Pharmaceuticals? Shares of ZNTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zentalis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zentalis Pharmaceuticals investors own include Tesla (TSLA), Iovance Biotherapeutics (IOVA), Nkarta (NKTX), Rocket Pharmaceuticals (RCKT), NIO (NIO), Alibaba Group (BABA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/09/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ZNTL's financial health is in the Red zone, according to TradeSmith. ZNTL has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ZNTL CIK1725160 Webwww.zentalis.com Phone212-433-3791FaxN/AEmployees106Year Founded2014Price Target and Rating Average Price Target for Zentalis Pharmaceuticals$8.29 High Price Target$11.00 Low Price Target$5.00 Potential Upside/Downside+509.2%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$137.06 million Net MarginsN/A Pretax MarginN/A Return on Equity-75.82% Return on Assets-55.15% Debt Debt-to-Equity RatioN/A Current Ratio7.33 Quick Ratio7.33 Sales & Book Value Annual Sales$67.43 million Price / Sales1.45 Cash FlowN/A Price / Cash FlowN/A Book Value$2.86 per share Price / Book0.48Miscellaneous Outstanding Shares71,670,000Free Float68,948,000Market Cap$97.47 million OptionableOptionable Beta1.91 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:ZNTL) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersEarly bird access on this Black Friday dealMarkham Trading's Alpha Oracle Signal system is just $7 for Black Friday. Others paid nearly $2,000 for access...TradeWins | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.